Difference between revisions of "Copanlisib (Aliqopa)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m |
||
| (8 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: From [http://www.cancer.gov/drugdictionary?CdrID=653981 NCI Drug Dictionary]: A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations.<ref name="insert">[http://labeling.bayerhealthcare.com/html/products/pi/Aliqopa_PI.pdf Copanlisib (Aliqopa) package insert]</ref><ref>[[ | + | Class/mechanism: From [http://www.cancer.gov/drugdictionary?CdrID=653981 NCI Drug Dictionary]: A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations.<ref name="insert">[http://labeling.bayerhealthcare.com/html/products/pi/Aliqopa_PI.pdf Copanlisib (Aliqopa) package insert]</ref><ref>[[:File:Copanlisib.pdf | Copanlisib (Aliqopa) package insert (locally hosted backup)]]</ref><ref>[http://aliqopa.com Aliqopa manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
| + | *[[Marginal zone lymphoma]] | ||
| − | ==History of changes in FDA indication== | + | ==History of changes in FDA indication - '''WITHDRAWN'''== |
| − | * | + | *2017-09-14: Granted accelerated approval for the treatment of adult patients with relapsed [[follicular lymphoma]] who have received at least two prior systemic therapies. ''(Based on CHRONOS-1)'' |
| + | **2024-03-18: Accelerated approval for the treatment of adult patients with relapsed [[follicular lymphoma]] who have received at least two prior systemic therapies withdrawn. | ||
| + | |||
| + | ==Patient Information== | ||
| + | *[http://labeling.bayerhealthcare.com/html/products/pi/Aliqopa_PI.pdf Copanlisib (Aliqopa) package insert]<ref name="insert"></ref> | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' BAY 80-6946 | + | *'''Code name:''' BAY-80-6946 |
*'''Brand name:''' Aliqopa | *'''Brand name:''' Aliqopa | ||
| Line 22: | Line 27: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | |||
[[Category:PI3K alpha inhibitors]] | [[Category:PI3K alpha inhibitors]] | ||
[[Category:PI3K delta inhibitors]] | [[Category:PI3K delta inhibitors]] | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
| + | [[Category:Marginal zone lymphoma medications]] | ||
[[Category:FDA approved in 2017]] | [[Category:FDA approved in 2017]] | ||
| + | [[Category:FDA withdrawn in 2024]] | ||
Latest revision as of 11:33, 9 April 2024
General information
Class/mechanism: From NCI Drug Dictionary: A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
History of changes in FDA indication - WITHDRAWN
- 2017-09-14: Granted accelerated approval for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. (Based on CHRONOS-1)
- 2024-03-18: Accelerated approval for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies withdrawn.
Patient Information
Also known as
- Code name: BAY-80-6946
- Brand name: Aliqopa